@zimbuckapp: BREAKING: Zura Bio crashes 76% after its skin-disease drug fails in Phase 2. Zura Bio (NASDAQ: ZURA) plunged about 76% to $0.97 after tibulizumab missed the main goal of the TibuSHIELD trial in hidradenitis suppurativa. In 247 patients, lesion counts fell 58.1% on 150mg and 56% on 300mg — barely ahead of 52.5% on placebo — and key secondary goals were also missed. Zura is stopping tibulizumab development for this condition, while continuing studies in systemic sclerosis and polymyalgia rheumatica. The company held $187.7M in cash at Sept 30, which it expects to fund operations through at least the end of 2028. #ZuraBio #Biotech #Stocks #StockMarket #ZURA #Pharma #Investing Read the full blog/news on Zimbuck: https://zimbuck.com/posts/2366 Join the conversation on Zimbuck — the finance social platform for traders & investors: https://zimbuck.com

There are no more comments for this video.

To see more videos from user @zimbuckapp, please go to the Tikwm homepage.